Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5080047
Max Phase: Preclinical
Molecular Formula: C51H63N7O6S2
Molecular Weight: 934.24
Molecule Type: Unknown
Associated Items:
ID: ALA5080047
Max Phase: Preclinical
Molecular Formula: C51H63N7O6S2
Molecular Weight: 934.24
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCCCCCCCCC(=O)Nc2ccc(C(=O)Nc3cc(-c4cccs4)ccc3N)cc2)C(C)(C)C)cc1
Standard InChI: InChI=1S/C51H63N7O6S2/c1-33-46(66-32-54-33)35-19-17-34(18-20-35)30-53-49(63)42-29-39(59)31-58(42)50(64)47(51(2,3)4)57-45(61)16-12-10-8-6-5-7-9-11-15-44(60)55-38-24-21-36(22-25-38)48(62)56-41-28-37(23-26-40(41)52)43-14-13-27-65-43/h13-14,17-28,32,39,42,47,59H,5-12,15-16,29-31,52H2,1-4H3,(H,53,63)(H,55,60)(H,56,62)(H,57,61)/t39-,42+,47-/m1/s1
Standard InChI Key: PYFJRWPCHWNACA-PDZNDIJHSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 934.24 | Molecular Weight (Monoisotopic): 933.4281 | AlogP: 9.33 | #Rotatable Bonds: 21 |
Polar Surface Area: 195.85 | Molecular Species: NEUTRAL | HBA: 10 | HBD: 6 |
#RO5 Violations: 3 | HBA (Lipinski): 13 | HBD (Lipinski): 7 | #RO5 Violations (Lipinski): 4 |
CX Acidic pKa: 12.67 | CX Basic pKa: 2.93 | CX LogP: 7.17 | CX LogD: 7.17 |
Aromatic Rings: 5 | Heavy Atoms: 66 | QED Weighted: 0.03 | Np Likeness Score: -0.82 |
1. Smalley JP, Baker IM, Pytel WA, Lin LY, Bowman KJ, Schwabe JWR, Cowley SM, Hodgkinson JT.. (2022) Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells., 65 (7.0): [PMID:35293758] [10.1021/acs.jmedchem.1c02179] |
Source(1):